These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1751786)

  • 21. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of dietary protein in the progression and symptomatology of chronic renal failure.
    Blachley JD
    Am J Med Sci; 1984 Dec; 288(5):228-34. PubMed ID: 6393762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibitors in chronic renal failure.
    Opsahl JA; Abraham PA; Keane WF
    Drugs; 1990; 39 Suppl 2():23-32. PubMed ID: 2188823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End-stage renal disease: can dietary protein restriction prevent it?
    Buckalew VM
    South Med J; 1994 Oct; 87(10):1034-7. PubMed ID: 7939916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of arterial hypertension in developement of chronic renal failure].
    Kes P; Basić-Jukić N; Ljutić D; Brunetta-Gavranić B
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():78-84. PubMed ID: 23120821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of the progression of renal failure in glomerular diseases].
    Ritz E; Siebels M; Fliser D
    Internist (Berl); 1993 Apr; 34(4):330-9. PubMed ID: 8486477
    [No Abstract]   [Full Text] [Related]  

  • 28. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of arterial hypertension in the progression of non-diabetic glomerular diseases.
    Ljutić D; Kes P
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v28-30. PubMed ID: 12817064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy.
    Bazzi C; Petrini C; Rizza V; Arrigo G; Beltrame A; Pisano L; D'Amico G
    Am J Kidney Dis; 2001 Aug; 38(2):240-8. PubMed ID: 11479148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
    Ciechanowicz A
    Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrosis causes progressive kidney failure.
    Cohen EP
    Med Hypotheses; 1995 Nov; 45(5):459-62. PubMed ID: 8748086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.
    Mulè G; Castiglia A; Cusumano C; Scaduto E; Geraci G; Altieri D; Di Natale E; Cacciatore O; Cerasola G; Cottone S
    Adv Exp Med Biol; 2017; 956():279-306. PubMed ID: 27873229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?
    Weir MR; Dworkin LD
    Am J Kidney Dis; 1998 Jul; 32(1):1-22. PubMed ID: 9669419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving strategies for renoprotection: non-diabetic chronic renal disease.
    Taal MW; Brenner BM
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):523-31. PubMed ID: 11458034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression to renal failure.
    Topaloğlu R
    Turk J Pediatr; 2005; 47 Suppl():3-8. PubMed ID: 15884660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.